


Celecoxib-d₃

| | | | |
|---------------------------|---|-------|----------|
| Cat. No.: | HY-14398S1 | | |
| CAS No.: | 544686-18-2 | | |
| Molecular Formula: | C ₁₇ H ₁₁ D ₃ F ₃ N ₃ O ₂ S | | |
| Molecular Weight: | 384.39 | | |
| Target: | COX | | |
| Pathway: | Immunology/Inflammation | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



BIOLOGICAL ACTIVITY

| | |
|--------------------|--|
| Description | Celecoxib-d ₃ is the deuterium labeled Celecoxib. Celecoxib, a selective non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC ₅₀ of 40 nM[1][2]. |
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.
- [2]. Liu DB, et al. Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation. *Acta Pharmacol Sin.* 2012 May;33(5):682-90.
- [3]. Penning TD, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzene sulfonamide (SC-58635, celecoxib). *J Med Chem.* 1997
- [4]. Hou XL, et al. Combination of fasudil and celecoxib promotes the recovery of injured spinal cord in rats better than celecoxib or fasudil alone. *Neural Regen Res.* 2015 Nov;10(11):1836-40.
- [5]. Suri A, et al. The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer. *Oncotarget.* 2016 Apr 8.
- [6]. Pobbati AV, et al. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy. *Theranostics.* 2020 Feb 18;10(8):3622-3635.
- [7]. Liu C, et al. Celecoxib alleviates nonalcoholic fatty liver disease by restoring autophagic flux. *Sci Rep.* 2018 Mar 7;8(1):4108.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA